525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors

• Hendrik-Tobias Arkenau,
• Emiliano Calvo,
• Alain Mita,
• Young Kwang Chae,
• Devalingam Mahalingam,
• Ugur Sahin,
• Elena Garralda,
• Oezlem Tuereci,
• Vladimir Galvao,
• Stefan Symeonides,
• Maria Miguel,
• Hariz Hassan,
• Annette Baumhauer,
• Timo Völker,
• Marie-Cristine Kühnle,
• Roman Rösemann,
• Stefan Strobl

Affiliations

Hendrik-Tobias Arkenau

Drug Development Unit, Sarah Cannon Research Institute and University College London Cancer Institute, London, UK

Emiliano Calvo

4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Alain Mita

Cedars-Sinai Medical Center, Los Angeles, California, USA

Young Kwang Chae

Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Devalingam Mahalingam

1Northwestern University Medical School, Chicago, IL, USA

Ugur Sahin

1BioNTech SE, Mainz, Germany

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Oezlem Tuereci

9BioNTech SE, Mainz, Germany

Vladimir Galvao

1Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

Stefan Symeonides

1Edinburgh Cancer Research Centre, University of Edinburgh, and Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK

Maria Miguel

3START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Hariz Hassan

7BioNTech SE, Mainz, Germany

Annette Baumhauer

7BioNTech SE, Mainz, Germany

Timo Völker

7BioNTech SE, Mainz, Germany

Marie-Cristine Kühnle

7BioNTech SE, Mainz, Germany

Roman Rösemann

7BioNTech SE, Mainz, Germany

Stefan Strobl

7BioNTech SE, Mainz, Germany